Mice with Pulmonary Tuberculosis Treated with Mycobacterium vaccae
Develop Strikingly Enhanced Recall Gamma Interferon Responses
to M. vaccae Cell Wall Skeleton by Rodríguez Güell, Elisabeth et al.
CLINICAL AND VACCINE IMMUNOLOGY, May 2008, p. 893–896 Vol. 15, No. 5
1556-6811/08/$08.000 doi:10.1128/CVI.00477-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Mice with Pulmonary Tuberculosis Treated with Mycobacterium vaccae
Develop Strikingly Enhanced Recall Gamma Interferon Responses
to M. vaccae Cell Wall Skeleton
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Whole heat-killed Mycobacterium vaccae is used as an immunotherapeutic agent in tuberculosis (TB), but the
compound(s) that triggers its immunostimulatory ability is not known. Here, we show that among different
subcellular fractions, the cell wall skeleton induced a prominent expression of gamma interferon in splenocytes
from both non-TB and TB M. vaccae-treated mice.
Immunotherapy agents for tuberculosis (TB) should down-
regulate or suppress the Th2 component and potentiate the
Th1 response to manifest a more protective antibacterial im-
munity (14). The induction of a favorable cytokine profile,
together with current chemotherapy, could improve the killing
of Mycobacterium tuberculosis. Accordingly, it was shown that
the immunization of mice with heat-killed Mycobacterium vac-
cae induces a predominantly Th1 cytokine profile and protec-
tion against M. tuberculosis (5). Furthermore, treatment with
heat-killed M. vaccae after intratraqueal infection with M. tu-
berculosis also caused a 1- to 2-log-unit decrease in bacterial
counts (6). In humans, numerous clinical trials using heat-
killed suspensions of M. vaccae have been carried out (12), but
to date, the main conclusion drawn is that its efficacy varies
between individuals and between populations studied (13).
It would be interesting to find out which M. vaccae com-
pounds induce the favorable cytokine profile. Using more pu-
rified components rather than the whole microorganism would
be advantageous for avoiding the presence of immunosuppres-
sive and/or toxic molecules or, from a pharmaceutical perspec-
tive, for achieving better standardization of the doses.
Here, we analyzed the antigenicities of different subcellular
M. vaccae fractions by determining the cytokine production
triggered by these fractions in splenocyte cultures from both
noninfected mice (non-TB mice) and M. tuberculosis-infected
mice (TB mice) that were recently treated with M. vaccae or
given control treatment.
Initially, a rough variant of M. vaccae ATCC 15483T (used in
some human studies) (12) was grown on tryptone soy agar
medium, collected, and heat killed at 121°C for 15 min. It was
then fractionated following a classic protocol (3). The first
fraction contained mainly noncovalently attached lipids and
glycolipids, which were controlled by thin-layer chromatogra-
phy (9). The second fraction, the cell wall skeleton (CWS),
contained the mycolyl-arabinogalactan-peptidoglycan complex
(3). Finally, the third fraction was composed of glycans, lipo-
glycans, and proteins (GP). The analysis of the last fraction
showed a constant content of sugars and proteins (18 to 21%
and 9 to 11%, respectively) (7, 10) in all M. vaccae fraction-
ations carried out. All fractions were frozen at 40°C until
they were used.
Four groups of 6- to 8-week-old specific-pathogen-free
BALB/c mice (Charles River, L’Arbresle Cedex, France) were
studied. The first group, non-TB mice, received only phos-
phate-buffered saline. In the second group, M. vaccae-treated
non-TB mice were treated with three doses of 107 or 109 M.
vaccae bacteria (11) intraperitoneally at weeks 0, 2, and 6 and
were sacrificed at week 8. The third group, untreated TB mice,
were infected with M. tuberculosis H37Rv (ATCC 27294T) (2).
They were sacrificed 16 weeks after infection. In the last group
(M. vaccae-treated TB mice), TB mice were treated 8 weeks
after infection with M. vaccae, following the same protocol as
for non-TB mice. All experimental procedures were approved
by the Ethical Committees for Animal Experimentation at our
institutions. After the mice were sacrificed by cervical disloca-
tion, splenocytes were cultured at 106 cells/ml as previously
described (9). The cells were stimulated with concanavalin A
(2.5 g/ml; Sigma Chemical Co., St. Louis, MO), M. vaccae, or
the different fractions (20 g/ml) or with medium alone as a
negative control. Culture supernatants were collected and cy-
tokine concentrations were measured by enzyme-linked immu-
nosorbent assays (ELISAs) using commercially available kits
(OptEIA Set, Becton Dickinson Biosciences, New Jersey, and
ELISA kits, Mabtech AB, Nacka Strand, Sweden) according to
the manufacturer’s instructions.
Mann-Whitney rank sum tests (Sigma Stat; SPSS Software)
were used to perform statistical comparisons. A P value of
0.05 was considered significant.
In non-TB mice (Fig. 1), M. vaccae and the CWS and GP
fractions triggered a higher production of gamma interferon
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FIG. 1. Higher IFN- and IL-10 production in splenocyte cultures stimulated with M. vaccae and CWS and GP fractions in M. vaccae-treated
mice compared to nontreated mice. Cytokine concentrations were measured in culture supernatants by ELISA. IL-12(p70) was measured after 48 h
of culture and IFN- and IL-10 after 72 h. The data are shown as mean values plus standard deviations obtained from four mice per group. PBS,
mice treated with PBS; MV 107, mice treated with 107 cells of M. vaccae; MV 109, mice treated with 109 cells of M. vaccae; NA, nonantigen; ConA,
concanavalin A; MV, heat-killed M. vaccae; L, lipids. , P  0.05; Mann-Whitney rank sum test.
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FIG. 2. Prominent IFN- production in splenocytes of M. vaccae-treated TB mice stimulated in vitro with CWS compared to that in splenocytes of M.
vaccae-treated TB mice stimulated with M. vaccae. Concentrations were measured in culture supernatants by ELISA. The data are shown as mean values plus
standard deviations obtained from four mice per group. TB, mice infected with M. tuberculosis; TB  MV 107, mice infected with M. tuberculosis and treated
with 107 cells of M. vaccae. NA, nonantigen; ConA, concanavalin A; MV, heat-killed M. vaccae; L, lipids. *, P  0.05; Mann-Whitney rank sum test.
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(IFN-) and interleukin 10 (IL-10) in cultures from M. vaccae-
treated mice than in those from non-M. vaccae-treated mice
(P  0.05). The proinflammatory/anti-inflammatory (IFN-/
IL-10) ratio (8) obtained in cultures of mice treated with 107
M. vaccae cells was higher than in those from animals treated
with 109 cells when cultures were stimulated with M. vaccae
(121 versus 30, respectively), CWS (27 versus 17), and GP
(177 versus 20). Thus, the TB mice were treated only with the
107-M. vaccae-cell dose.
In TB mice, M. vaccae, CWS, and GP induced higher
IFN- production in cultures from M. vaccae-treated TB mice
than in untreated TB mice (Fig. 2). When the responses of
antigens in M. vaccae-treated TB mice were compared, re-
markably, CWS-induced IFN- production was 3.3 times
higher (143.5  10.1 ng/ml) than that induced by M. vaccae
(43.1  17.7 ng/ml). CWS-induced IL-10 production was
higher than that triggered by M. vaccae (1.6 times) (Fig. 2C).
The IFN-/IL-10 ratio was clearly higher in CWS- and GP-
stimulated cultures (128 and 129, respectively) than in M. vac-
cae-stimulated cultures (a ratio of 63) in M. vaccae-treated TB
mice.
Our results show that the CWS fraction provides antigens
for recall of adaptive T-cell IFN- responses, essential to po-
tentiate host resistance to M. tuberculosis. Interestingly, this
response is especially remarkable in TB mice, being higher
than that induced by the whole heat-killed mycobacteria. This
could mean that the activities of the immunostimulatory com-
ponents are masked in the whole M. vaccae by the interference
of some other mycobacterial compounds present in the bacte-
ria. The CWS fraction mainly contains the mycolyl-arabino-
galactan-peptidoglycan complex (3, 16). Although the immu-
nogenic ability of this macromolecule has not been described
before for M. vaccae, studies of Mycobacterium bovis bacillus
Calmette-Guérin have directly related it to the stimulation of
the immune system. The peptidoglycan portion appears to be
the obvious unit for the induction of Toll-like receptor 2 and 4
signaling in macrophages and dendritic cells (16), causing a
cascade of events that finally promotes lymphocyte activation
and the subsequent release of proinflammatory cytokines, such
as IFN- (15).
Although to a lesser extent, M. vaccae treatment also elicits
an increased IL-10 response. As shown in Fig. 1, immunization
is required; therefore, it is probably not innate anti-inflamma-
tory responses from macrophages. Studies using animal mod-
els of allergy have demonstrated that M. vaccae administration
induces the production of IL-10-producing regulatory T cells
(1, 17). However, IL-10 can also be produced by Th1, as has
been described in TB patients (4), or Th2 cells. Thus, the
cellular source of this cytokine should be further analyzed.
We demonstrated that the CWS fraction of M. vaccae elicits
a prominent recall IFN- response in TB mice in comparison
to the whole bacteria. These results warrant further research to
test the potentially immunotherapeutic properties of this frac-
tion.
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00099), the Fundació La Marató de TV3 (041230/1), and the Fun-
dación Ma Francisca de Roviralta.
REFERENCES
1. Adams, V. C., J. R. F. Hunt, R. Martinelli, R. Palmer, G. A. W. Rook, and
L. R. Brunet. 2004. Mycobacterium vaccae induces a population of pulmonary
CD11c cells with regulatory potential in allergic mice. Eur. J. Immunol.
34:631–638.
2. Cardona, P. J., E. Julián, X. Vallès, S. Gordillo, M. Muñoz, M. Luquin, and
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